Masimo wins CE Mark for MightySat Rx pulse oximeter

Masimo (NSDQ:MASI) said today that it won CE Mark approval in the European Union for its MightySat Rx pulse oximeter.

The device is designed to noninvasively check oxygen saturation and pulse rate for adults and children during motion and low perfusion, the company said.

“Many clinicians around the world rely on pulse oximetry as the 5th vital sign. The MightySat Rx represents a significant milestone. To deliver Masimo SET performance in this low-power form factor took some engineering, given the precision of our technology and SET’s computationally intensive algorithm. We actually dropped the power consumption by nearly two orders of magnitude. But the development effort was worth it, as we expect this technology will empower clinicians and they will no longer have to compromise performance for mobility,” CEO Joe Kiani said in a press release.

The Irvine, Calif.-based company said the device will be available with bluetooth to allow clinicians to track up to 12 hours of measurements via smartphone and allow patients to connect the data to Apple‘s (NSDQ:AAPL) health app.

A version that allows patients to measure pleth variability index will also be available, Masimo said.

Last week, Masimo won CE Mark approval for its Root patient monitoring platform with blood pressure and temperature capabilities.

The post Masimo wins CE Mark for MightySat Rx pulse oximeter appeared first on MassDevice.

from MassDevice http://ift.tt/1CoGrCt